ASEPA NEWS
ASEPA NEWSLETTERS
January 2020 Newsletter
July 2019 Newsletter
​
CMHC Monthly Newsletter:
cardiometabolichealth.org/newsletter.html
​
RECENT NEWS
June 2023
Empagliflozin is now approved in kids with T2DM down to age 10. https://www.medscape.com/viewarticle/993480?src=FYE
​
The FDA and Novo Nordisk warn of Counterfeit Semaglutide pens:
​
​
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is now available for treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). And for the replacement of endogenous GH in adults with growth hormone deficiency (GHD).
​
May 2023:
Novel insulin pump recently cleared by FDA
https://www.medscape.com/viewarticle/992221?src=FYE
​
May 2023:
FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death (CV), hospitalization for heart failure (HF), and urgent HF visit in adults with HF regardless of left ventricular ejection fraction (LVEF) status. Previously it had only been approved for HF patients with reduced ejection fraction (HFrEF).
​
March 2022:
FDA approves DEXCOM G7
FDA approves Freestyle Libre 3
FDA approves Tzield
​
May 17, 2022:
FDA approves Mounjaro (tirzepatide)
FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes
​
January 28, 2022:
OmniPod 5 approved by the FDA
https://diatribe.org/omnipod-5-approved-fda
​
​
​
​
MEETINGS
ASEPA members meet twice a year at the following conferences: AAPA and AACE. We also meet informally at the MEDS East and MEDS West conferences.
Throughout the year, board members communicate frequently via email and conference calls.